Each of these companies has the potential to generate life-changing returns.
News & Analysis: Provention Bio Inc
PRVB earnings call for the period ending June 30, 2020.
Provention Bio is developing a drug that could delay the onset of diabetes, and if it's successful, the company's stock could soar.
The company announced a public offering of common stock.
The company released positive data from a clinical trial for one of its pipeline candidates.
PRVB earnings call for the period ending March 31, 2020.
The decision was made to protect the safety of those involved.
PRVB earnings call for the period ending December 31, 2019.
It's a $45 billion market -- here are some winners that could keep winning.
Seven biotechs led the way.